Sir, Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin
We have read with interest the article of Wefers Bettink-Remeijer et al., 1 who described a case series of five patients presenting an acute iris depigmentation, masquerading as uveitis, following moxifloxacin treatment. They suggest that this new syndrome is multifactorial and that moxifloxacin use is one of the precipitating factors. In our clinic, we have followed up a patient with a similar history who had also a possible additional risk factor.
Case report
A 36-year-old man presented to our department for acute bilateral pain and vision impairment. Ten days earlier he was treated in another institution with topical steroids for a bilateral mild uveitis that occurred 2 weeks after treatment with moxifloxacin (Avelox) for otitis. Symptoms did not improve and the patient was given oral and subconjunctival steroids with a topical betablocker. However, the situation continued to get worse and the patient came to our clinic. His visual acuity was 1/10 in both eyes. Slit lamp examination showed fine pigment keratic precipitates, many pigment granules, and few non-pigmented cells in the anterior chamber. Intraocular pressure was 46 mm Hg in both eyes. The angles were open but heavily pigmented. The iris was intensively depigmented (Figure 1) . OCT of the angles demonstrated a concave iris ( Figure 2 ). Steroids were stopped, antiglaucomatous therapy and oral acetazolamide were prescribed, but the clinical picture remains uncontrolled. An anterior chamber tap was performed and PCR for herpes viruses was negative. After the tap, the amount of pigment in the anterior chamber decreased significantly but IOP remain elevated despite strong anti-glaucomatous medication. Finally, IOP could be controlled after laser iridoplasty, which normalised the shape of the iris.
Comment
As predicted by the authors, our case report further confirms that moxifloxacin can induce the development of a pseudouveitis characterised by an acute depigmentation of the iris. In addition, this case also suggests that a concave shape of the iris could be another triggering element. In this setting, IOP might be dangerously elevated and laser iridoplasty recommended.
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2 None of our patients had visible pigment in the chamber angle. None of our patients had an alteration of Correspondence visual acuity. None of our patients needed more than a short course of steroid drops. Although we do not know which other factors are causing the development of depigmentation of the iris, in none of our patients a concave iris has been the primary factor. Gonioscopy did not reveal pigmentation of the chambre angle. In addition, in pigment glaucoma the pattern of translucency of the iris differs from the pattern seen here, which is similar to the pattern in our patients. In any patient with iris translucency it is wise to evaluate the concavity of the iris by gonioscopy, but it is also possible that in this patient the subconjunctival steroid injection is one of the factors for developing glaucoma.
Sir, Intravitreal ranibizumab for choroidal neovascularisation secondary to pathologic myopia: 12 month results
We read with interest the article 'Intravitreal ranibizumab for choroidal neovascularisation secondary to pathologic myopia: 12 month results'. We noted that the study group was very diverse with regard to age and incorporated people with myopia ranging from À5 to À18 D. We would like further clarification whether Monés et al 1 used refraction as the only assessment of myopia. We believe that some of the more elderly patients may have had a myopic shift related to lenticular changes. The axial length would have given further support to determine the true pathological myopia, and we are interested to know whether this was measured. The number of injections of ranibizumab is very low compared with that often reported for age-related macular degeneration and choroidal neovascularisation. For example, a recent study 2 on the frequency of injections needed stated 5.2 as the mean number of injections vs 1.52 in this article. Of interest is the finding by Ruiz-Moreno et al
